Merck to Drop Price as Zocor Patent Lapses
The first generic versions of the popular cholesterol pill Zocor were approved by the Food and Drug Administration. The patent on Zocor, held by pharmaceutical company Merck, has run out, and that means the price for the pills will drop, as Merck has made an unusual decision to lower the price of Zocor to compete with the generics.
The decision may be bad news for Pfizer, which makes Lipitor, another popular cholesterol medication. Michele Norris talks with cardiologist Stuart Seides, associate director of cardiology at Washington Hospital Center.
Comments
Discussions for this story are now closed. Please see the Community FAQ for more information.